Is MOTS-c approved or legal?

No. MOTS-c is not approved by the FDA or other major regulators as a medicine. It is sold as a research-use-only compound, not for human consumption, and is being studied in early-phase human trials as of 2026. Legality of possession varies by jurisdiction; it is not a legal therapeutic product.

What is the half-life and how is it dosed?

MOTS-c is thought to have a short half-life (roughly 1-2 hours), which is why community guides favor smaller, more frequent subcutaneous doses. There is no established clinical human dose; any protocols you see online are anecdotal and not medical advice.

How does MOTS-c work?

It is believed to activate AMPK, a key cellular energy sensor, partly by disrupting the folate cycle and raising AICAR. In muscle this is linked to better glucose uptake and insulin sensitivity. These mechanisms are mainly shown in animal and cell studies.

Does MOTS-c actually help with fat loss or endurance in humans?

The benefits seen for metabolism and exercise capacity come mostly from rodent studies, plus observations that natural MOTS-c rises with exercise. Controlled human trials of injected MOTS-c are ongoing but not yet conclusive, so human benefit is unproven.

Human safety has not been established. Animal studies suggest a relatively favorable short-term profile, and self-reported side effects are usually mild (injection-site irritation, flushing, fatigue, headache, occasional palpitations or insomnia). Long-term risks are unknown; consult a clinician.

Metabolic

MOTS-c

Also known as: Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial open reading frame of the 12S rRNA-c, MOTS-C

Mitochondrial-derived peptide studied preclinically for AMPK activation, insulin sensitivity and exercise capacity; no approved human therapy.

Last updated July 11, 2026

Reconstitute this peptide Buy MOTS-c

Overview

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. First described by Lee and colleagues in 2015, it is one of several so-called mitochondrial-derived peptides (alongside humanin) thought to act as signaling molecules that help coordinate cellular metabolism and stress responses. Endogenous MOTS-c rises with exercise in human skeletal muscle and circulation, which has driven interest in it as a potential "exercise-mimetic" and metabolic-aging target. Most of the evidence base is preclinical. In rodents and cell models, exogenous MOTS-c has improved insulin sensitivity, reduced diet-induced obesity, and enhanced physical capacity in young, middle-aged and old animals. Human data so far is largely observational (measuring natural MOTS-c levels in response to exercise) rather than from controlled trials of injected MOTS-c. As of 2026, MOTS-c is being evaluated in early human clinical trials (e.g., a Phase 2a study in prediabetes/overweight adults), but it is not an approved drug anywhere and remains a research compound. Material sold to consumers is research-use-only and not validated for human consumption. Claims about fat loss, endurance and "anti-aging" benefits in people should be treated cautiously: they are extrapolated mainly from animal studies and community anecdote, not from completed human efficacy trials.

How it works

MOTS-c is proposed to act primarily by activating AMP-activated protein kinase (AMPK), a master regulator of cellular energy balance. Mechanistic work suggests it interferes with the folate-methionine cycle and de novo purine biosynthesis, causing accumulation of the intermediate AICAR, which in turn activates AMPK. Downstream effects in skeletal muscle (its apparent main target) include increased GLUT4-mediated glucose uptake and improved insulin sensitivity. Under metabolic stress, MOTS-c can also translocate from mitochondria to the nucleus and modulate stress-responsive nuclear gene expression in an AMPK-dependent manner. These mechanisms are established mostly in cell and animal models; human mechanistic confirmation is limited.

Researched effects

Preclinical Improves insulin sensitivity and glucose handling
Preclinical Reduces diet-induced obesity and supports metabolic homeostasis
Preclinical Enhances physical/exercise capacity and offsets age-related physical decline
Preclinical Activates AMPK signaling in skeletal muscle
Clinical Endogenous levels rise with exercise in humans (biomarker, not a treatment effect)
Preclinical May reduce muscle atrophy / myostatin signaling
Anecdotal Self-reported improved energy, endurance and fat loss with injected MOTS-c

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established clinical dosing in humans. MOTS-c is not an approved therapy; dosing is being explored in early-phase trials (e.g., subcutaneous administration over ~12 weeks in prediabetes/overweight adults) and standardized human therapeutic doses have not been published.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only - not medical advice or an instruction to dose. Community guides and forum posts (including r/Peptides) commonly describe subcutaneous protocols around 5 mg, 2-3 times per week (e.g., Mon/Wed/Fri), sometimes titrating within a roughly 5-15 mg/week range, run in cycles of about 4-8 weeks with breaks. Smaller, more frequent dosing is rationalized by the peptide's short estimated half-life. These figures come from vendor guides and self-experimenters, are not validated by human trials, and carry unknown long-term risk.

Half-life: Estimated short (~1-2 hours); exercise-induced circulating MOTS-c returns to baseline within ~4 hours. The pharmacokinetic half-life of injected MOTS-c in humans has not been formally established.
Routes: subcutaneous

Safety & side effects

Human safety has not been established; long-term data in people is lacking. Rodent studies up to several weeks generally showed no overt toxicity. Reported side effects from guides and self-experimenters (anecdotal) include injection-site redness/irritation, flushing or skin warmth, fatigue, headache, insomnia, and palpitations/increased heart rate. Because it influences glucose metabolism, caution is warranted in people on diabetes medication (theoretical additive blood-sugar effects). Product purity and sterility are real concerns with research-grade peptides. Research-use-only; not for human consumption. Consult a qualified clinician before considering any use.

Research summary

The strongest evidence for MOTS-c is preclinical. The foundational 2015 Cell Metabolism paper (Lee et al.) identified MOTS-c and showed exogenous administration improved insulin sensitivity and reduced diet-induced obesity in mice via an AMPK-linked mechanism. A 2018 Cell Metabolism study described its stress-induced nuclear translocation and regulation of gene expression. A 2021 Nature Communications study (Reynolds et al.) reported that exercise induces MOTS-c in humans and that intermittent MOTS-c improved physical capacity across age groups in mice. Human evidence to date is mostly observational, documenting that endogenous MOTS-c rises with acute and chronic exercise. This supports its biological relevance but does not demonstrate that injecting MOTS-c produces clinical benefits in people. As of 2026, controlled human efficacy trials of exogenous MOTS-c (e.g., a Phase 2a study in prediabetes/overweight adults) are underway but not yet conclusive. Overall, MOTS-c is a scientifically interesting metabolic and longevity candidate with promising animal data, an unestablished human efficacy and safety profile, and a community of self-experimenters whose protocols are not evidence-based. It should be framed as an investigational, research-use-only compound rather than a proven treatment.

FAQ

Is MOTS-c approved or legal?: No. MOTS-c is not approved by the FDA or other major regulators as a medicine. It is sold as a research-use-only compound, not for human consumption, and is being studied in early-phase human trials as of 2026. Legality of possession varies by jurisdiction; it is not a legal therapeutic product.
What is the half-life and how is it dosed?: MOTS-c is thought to have a short half-life (roughly 1-2 hours), which is why community guides favor smaller, more frequent subcutaneous doses. There is no established clinical human dose; any protocols you see online are anecdotal and not medical advice.
How does MOTS-c work?: It is believed to activate AMPK, a key cellular energy sensor, partly by disrupting the folate cycle and raising AICAR. In muscle this is linked to better glucose uptake and insulin sensitivity. These mechanisms are mainly shown in animal and cell studies.
Does MOTS-c actually help with fat loss or endurance in humans?: The benefits seen for metabolism and exercise capacity come mostly from rodent studies, plus observations that natural MOTS-c rises with exercise. Controlled human trials of injected MOTS-c are ongoing but not yet conclusive, so human benefit is unproven.
Is MOTS-c safe?: Human safety has not been established. Animal studies suggest a relatively favorable short-term profile, and self-reported side effects are usually mild (injection-site irritation, flushing, fatigue, headache, occasional palpitations or insomnia). Long-term risks are unknown; consult a clinician.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.